Top

Published in:

01-11-2009 | Original Article

Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients

Authors: Wei-Jie Yuan, Jie Ge, Zhi-Kang Chen, Shao-Bin Wu, Hong Shen, Pu Yang, Bin Hu, Ge-Wen Zhang, Zi-Hua Chen

Published in: Digestive Diseases and Sciences | Issue 11/2009

Abstract

This study aims to investigate the expression and significance of EphA2 and EphrinA-1 in human gastric adenocarcinoma progression and prognosis. The expression of EphA2 and EphrinA-1 was detected in the cell lines and tissues of gastric adenocarcinoma. Different expression levels of EphA2 and EphrinA-1 were found in two cell lines. The expression of EphA2 and EphrinA-1 was significantly higher in gastric adenocarcinoma tissues than in normal tissues. Statistical analysis showed a significant correlation of EphA2 expression with the depth of tumor invasion, tumor-node-metastasis (TNM) stages, and lymph node metastasis. EphrinA-1 over-expression was significantly correlated with TNM stages and lymph node metastasis, while EphA2 expression was found to be an independent prognostic factor of postoperative gastric adenocarcinoma. In conclusion, the increased expression of EphA2 and EphrinA-1 plays an important role in the progression of human gastric adenocarcinoma, in which elevated EphA2 expression is an independent factor that indicates poor prognosis in postoperative gastric adenocarcinoma.

American Cancer Society. Cancer facts and figures 2005. Available online at: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf.

Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hematol, 2005;54:209–241. doi:10.1016/j.critrevonc.2005.01.002.CrossRefPubMed

American Cancer Society. Cancer facts and figures 2008. Available online at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.

van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol, 1994;10:251–337. doi:10.1146/annurev.cb.10.110194.001343.CrossRefPubMed

Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev, 2004;15:419–433. doi:10.1016/j.cytogfr.2004.09.002.CrossRefPubMed

Sulman EP, Tang XX, Allen C, et al. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics, 1997;40:371–374. doi:10.1006/geno.1996.4569.CrossRefPubMed

Zelinski DP, Zantek ND, Stewart JC, et al. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res, 2001;61:2301–2306.PubMed

Kinch MS, Moore MB, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res, 2003;9:613–618.PubMed

Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci, 2004;95:136–141. doi:10.1111/j.1349-7006.2004.tb03194.x.CrossRefPubMed

10.

Xu F, Zhong W, Li J, et al. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res, 2005;25:2943–2950.PubMed

11.

Ogawa K, Pasqualini R, Lindberg RA, et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene, 2000;19:6043–6052. doi:10.1038/sj.onc.1204004.CrossRefPubMed

12.

Fang WB, Brantley-Sieders DM, Parker MA, et al. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene, 2005;24:7859–7868. doi:10.1038/sj.onc.1208937.CrossRefPubMed

13.

Barranco SC, Townsend CM Jr, Casartelli C, et al. Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res, 1983;43:1703–1709.PubMed

14.

Lin CH, Fu ZM, Liu YL, et al. Investigation of SGC-7901 cell line established from human gastric carcinoma cells. Chin Med J, 1984;97:831–834.PubMed

15.

Sobin LH, Wittekind Ch. International Union Against Cancer. TNM Classification of Malignant Tumors, 5th edn. New York: Wiley; 1997.

16.

Herath NI, Spanevello MD, Sabesan S, et al. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer, 2006;6:144. doi:10.1186/1471-2407-6-144.CrossRefPubMed

17.

Shen H, Zhang M, Minuk GY, et al. Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol, 2002;3:9. doi:10.1186/1471-2121-3-9.CrossRefPubMed

18.

Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res, 2004;10:5145–5150. doi:10.1158/1078-0432.CCR-03-0589.CrossRefPubMed

19.

Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer, 2007;109:332–340. doi:10.1002/cncr.22415.CrossRefPubMed

20.

Nakamura R, Kataoka H, Sato N, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci, 2005;96:42–47.PubMed

21.

Abraham S, Knapp DW, Cheng L, et al. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res, 2006;12:353–360. doi:10.1158/1078-0432.CCR-05-1505.CrossRefPubMed

22.

Zantek ND, Walker-Daniels J, Stewart J, et al. MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res, 2001;7:3640–3648.PubMed

23.

Walker-Daniels J, Riese DJ 2nd, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res, 2002;1:79–87.PubMed

24.

Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis, 2003;20:59–68. doi:10.1023/A:1022546620495.CrossRefPubMed

25.

Wu D, Suo Z, Kristensen GB, et al. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol, 2004;94:312–319. doi:10.1016/j.ygyno.2004.05.019.CrossRefPubMed

26.

Han L, Dong Z, Qiao Y, et al. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol, 2005;99:278–286. doi:10.1016/j.ygyno.2005.06.036.CrossRefPubMed

27.

Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res, 1999;76:1–20. doi:10.1016/S0065-230X(08)60772-1.CrossRefPubMed

28.

Fang WB, Ireton RC, Zhuang G, et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci, 2008;121:358–368. doi:10.1242/jcs.017145.CrossRefPubMed

29.

Brantley-Sieders DM, Zhuang G, Hicks D, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest, 2008;118:64–78. doi:10.1172/JCI33154.CrossRefPubMed

30.

Easty DJ, Guthrie BA, Maung K, et al. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res, 1995;55:2528–2532.PubMed

31.

Duxbury MS, Ito H, Zinner MJ, et al. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene, 2004;23:1448–1456. doi:10.1038/sj.onc.1207247.CrossRefPubMed

32.

Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res, 2005;65:6910–6918. doi:10.1158/0008-5472.CAN-05-0530.CrossRefPubMed

Title: Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients
Authors: Wei-Jie Yuan
Jie Ge
Zhi-Kang Chen
Shao-Bin Wu
Hong Shen
Pu Yang
Bin Hu
Ge-Wen Zhang
Zi-Hua Chen
Publication date: 01-11-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 11/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0649-4

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients

Abstract

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2009

Home Telemanagement for Patients with Ulcerative Colitis (UC HAT)

Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Meta-Analysis of Randomized and Controlled Treatment Trials for Achalasia

Clinicopathological Conference: Fibrosing Cholestatic Hepatitis Presenting as Subacute Hepatic Failure in a Non-transplant Patient

Endoscopic Hemostasis in Nonvariceal Upper Gastrointestinal Bleeding: Comparison of Physician Practice in the East and the West

Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page